Table 2.
Cases/1000 person-years | Rate (per 1000 person-years) | HR | 95% CI | p Value | |
LMR | |||||
>3.20 | 11 | 34.66 | 0.34 | 0.16 to 0.74 | 0.004 |
≤3.20 | 16 | 101.28 | 1 | ||
NLR | |||||
>2.18 | 18 | 67.37 | 1.56 | 0.70 to 3.47 | 0.273 |
≤2.18 | 9 | 43.23 | 1 | ||
FLIPI | |||||
High risk | 19 | 82.30 | 2.52 | 1.10 to 5.75 | 0.023 |
Low/intermediate risk | 8 | 32.72 | 1 | ||
Sex | |||||
Male | 15 | 58.96 | 1.09 | 0.51 to 2.32 | 0.831 |
Female | 12 | 54.29 | 1 | ||
Rituximab | |||||
Yes | 4 | 22.02 | 0.28 | 0.10 to 0.81 | 0.012 |
No | 23 | 78.31 | 1 | ||
Year of diagnosis | |||||
2010–2014 | 1 | 8.71 | 0.10 | 0.01 to 0.75 | 0.006 |
2006–2010 | 5 | 43.05 | 0.50 | 0.19 to 1.33 | 0.157 |
2000–2005 | 21 | 85.91 | 1 |
FLIPI, Follicular Lymphoma International Prognostic Index; LMR, lymphocyte-to-monocyte ratio; NLR neutrophil-to-lymphocyte ratio; PFS, progression-free survival.